CV Risk Stratification Decision Factors

Check out this list of our top 5 most read cardiology stories from the year 2024.

Kathryn Litten, PharmD, discussed the pharmacist’s role in helping patients manage metabolic dysfunction-associated steatotic liver disease.

John Bucheit, PharmD, joined Drug Topics to discuss statins and nonstatins’ efficacy in treating cardiovascular disease.

Patients with ASCVD experienced a more significant reduction in LDL-C.

This approval marks the availability of the first near-complete stabilizer of transthyretin.

Results of a study at the Veterans Health Administration found that feedback and education led to better medication outcomes for patients.